227 related articles for article (PubMed ID: 21402296)
1. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
[TBL] [Abstract][Full Text] [Related]
2. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Giuliani J; Fiorica F; Sacchetto A; Franceschini G; Vaccari F; Bonetti A
J Oncol Pharm Pract; 2021 Mar; 27(2):445-447. PubMed ID: 33356990
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.
Vissers D; Stam W; Nolte T; Lenre M; Jansen J
Curr Med Res Opin; 2010 May; 26(5):1037-45. PubMed ID: 20199140
[TBL] [Abstract][Full Text] [Related]
4. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain.
Ruggeri M; Turriziani A; Oradei M
Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):459-64. PubMed ID: 24702061
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
9. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
Jandhyala R; Fullarton J
BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
[TBL] [Abstract][Full Text] [Related]
10. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects.
Nave R; Schmitt H; Popper L
Drug Deliv; 2013; 20(5):216-23. PubMed ID: 23650968
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; OroĊska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
13. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl for breakthrough pain: a systematic review.
Davis MP
Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
[TBL] [Abstract][Full Text] [Related]
17. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
18. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]